NextPlat (NXPL) Change in Accured Expenses (2010 - 2026)
NextPlat's (NXPL) quarterly Change in Accured Expenses came in at $1.8 million in Q2 2026, up 178.2% year-over-year from $650981.8 in Q2 2025, and up 2563.24% quarter-over-quarter from $68000.0 in Q1 2026.
Analysis
NextPlat (NXPL) Change in Accured Expenses (2010 - 2026) Analysis & Trends
NextPlat (NXPL) has reported Change in Accured Expenses for 16 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Change in Accured Expenses rose 178.2% year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was $5.1 million, a 175.84% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 119.44% from the prior year.
- Change in Accured Expenses was $1.8 million for Q2 2026 at NextPlat, up from $68000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $4.4 million in Q3 2023 and troughed at -$3.3 million in Q3 2024.
- A 5-year average of $38944.4 and a median of $81000.0 in 2023 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses surged 323228.38% in 2023 and plunged 843.29% in 2024, its largest moves.
- Over 5 years, Change in Accured Expenses stood at $429300.0 in 2022, then slumped by 306.62% to -$887000.0 in 2023, then slumped by 56.71% to -$1.4 million in 2024, then surged by 246.69% to $2.0 million in 2025, then slipped by 11.18% to $1.8 million in 2026.
- The last three Change in Accured Expenses figures came in at $1.8 million (Q2 2026), $68000.0 (Q1 2026), and $2.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 82.00 Mn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | - |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | -111.90 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 66.66 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 73.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | - |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | 3.62 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 1.96 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 1.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.81 Mn |
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | 2.04 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | -2.32 Mn |
| Mar 31, 2025 | 239,000.00 |
| Dec 31, 2024 | -1.39 Mn |
| Sep 30, 2024 | -3.30 Mn |
| Jun 30, 2024 | -3.09 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Dec 31, 2023 | -887,000.00 |
| Sep 30, 2023 | 4.35 Mn |
| Jun 30, 2023 | -328,000.00 |
| Mar 31, 2023 | 94,000.00 |
| Dec 31, 2022 | 429,300.00 |
| Sep 30, 2022 | 1,346.00 |
| Jun 30, 2022 | -329,847.00 |
| Mar 31, 2022 | 352,201.00 |
| Dec 31, 2021 | 179,298.00 |
| Sep 30, 2021 | -830,579.00 |